Related Experiment Videos
Herbal medicine for dementia: a systematic review
Brian H May1, M Lit, Charlie C L Xue
1WHO Collaborating Centre for Traditional Medicine, School of Health Sciences, RMIT University, Australia.
Phytotherapy Research : PTR
|December 17, 2008
Summary
Herbal medicines show promise in managing dementia symptoms, offering benefits comparable to pharmaceutical interventions. This review found certain herbal medicines effective and safe for dementia care with no severe adverse events reported.
Area of Science:
- Pharmacology
- Neurology
- Integrative Medicine
Background:
- Dementia presents a significant global health challenge with limited effective treatments.
- Herbal medicines (HM) have a long history of use in traditional medicine for various ailments.
- Assessing the scientific evidence for HM in dementia management is crucial.
Purpose of the Study:
- To systematically review the effectiveness and safety of herbal medicines for dementia treatment.
- To synthesize findings from randomized controlled trials (RCTs) comparing HM with placebo, no treatment, or pharmaceutical interventions.
- To exclude studies on Ginkgo biloba to avoid redundancy with existing reviews.
Main Methods:
- Searched English and Chinese databases from inception to February 2007.
- Included RCTs with Jadad Scale scores of 3 or higher.
- Excluded trials on Ginkgo biloba and its extracts.
- Performed meta-analyses on cognitive performance outcomes.
Main Results:
- Thirteen RCTs met the inclusion criteria.
- Herbal medicines demonstrated significant improvements in dementia symptoms across all included studies.
- Meta-analyses indicated HM were more effective than placebo or no treatment and equivalent to pharmaceutical interventions.
- No severe adverse events were reported in the trials.
Conclusions:
- Certain herbal medicines show positive evidence for effectiveness and safety in dementia management.
- HM can be considered a viable option for improving cognitive symptoms in dementia patients.
- Further research may explore specific HM formulations and long-term efficacy.
Related Concept Videos
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...